The purpose of this application is to provide continued access to NCI supported Cancer Treatment, Prevention and Control Trials for residents of the mid-gulf coast region. The MBCCOP in Mobile, AL is the only institution between New Orleans and Eastern Florida funded to provide these programs. The UAB in Birmingham AL is 260 miles distant. The MBCCOP in Mobile AL has existed and been funded since the inception of the program 12 years ago. The patient population in Mobile and environs is ideal for this type program because it is 35 percent African American and 2 percent other minorities. Further, about 60 percent of the population live in an urban environment and 40 percent in rural areas. This permitted the development of a MBCCOP at the University of South Alabama (USAMC) in 1990 and the development of affiliations with SWOG, NSABP, RTOG, MDA, URCC and POG (COG) with participation in Cancer Treatment, Prevention and Control Studies and development of local studies to determine reasons for differences in participation in trials by different ethnic groups. During 2000 the University indicated they were interested in pharmacological drug development and Phase I studies internally and with Pharmaceutical firms externally. The Mobile Infirmary Medical Center (MIMC) indicated an interest in the MBCCOP program and a Letter of Relinquishment of the program and grant was proffered by USAMC in favor of MIMC. Funding of MIMC for the remaining two years of the grant was provided by NCI following a site visit by DCP. The PI and CRA's at USAMC moved with the program to MIMC on 06/01/2001. The staff at MIMC had been a satellite of Tulane University for SWOG, RTOG and NSABP; this facilitated development of the MBCCOP at the new location. Most oncology patients at USA sought medical care at MIMC with closure of medical oncology at USA. Some were prohibited by third party payers. Followup is being accomplished by telephone and help of community physicians. All medical records were reproduced with individual patient permission. IRB approval of all protocols was necessary at MIMC and this slowed accrual because of inability of the IRB to review adequately 88 protocols abruptly. Most of the transition is completed; Cancer Treatment and Prevention Trials are operational and Cancer Control protocols are being activated. Membership in NCCTG is sought to increase accrual to Cancer Control protocols. Adequacy of the new program is attested by passing five audits by national research bases during the first year of operation (RTOG, SWOG, ACOSOG, NSABP-Treatment, and NSABP-Prevention). Genesis of the MBCCOP at MIMC was associated with increased accrual to NCI supported research over previous years.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (J1))
Program Officer
Mccaskill-Stevens, Worta J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mobile Infirmary Medical Center
United States
Zip Code
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Nahleh, Z A; Barlow, W E; Hayes, D F et al. (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158:485-95
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Malhotra, Binu; Moon, James; Kucuk, Omar et al. (2014) Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329. Head Neck 36:1712-7
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70

Showing the most recent 10 out of 97 publications